Please find two links to press releases issued this week by Agenus www.agenusbio.com. One (press release can be found here) announces the positive clinical testing of a malaria vaccine by GSK containing the proprietary Agenus adjuvant QS-21, and the other one (press release can be found here) reports the unrivalled efficacy of a new GSK shingles vaccine, especially in an older population. This vaccine candidate also contains QS-21, and Agenus is entitled to royalties on these vaccines.